MEGF0444A + carboplatin + paclitaxel + bevacizumab

This is a fixed-dose **combination regimen** consisting of four agents: - **MEGF0444A**, a humanized monoclonal antibody targeting Delta-like ligand 4 (DLL4) in the Notch signaling pathway, designed as an experimental anti-cancer therapy (developed by Genentech). - **Carboplatin**, a small-molecule platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis. - **Paclitaxel**, a small-molecule chemotherapeutic agent that stabilizes microtubules and inhibits cell division. - **Bevacizumab** (brand name Avastin), a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), blocking angiogenesis. This combination was tested specifically in **advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)**. MEGF0444A is a novel DLL4 inhibitor, and when combined with standard-of-care carboplatin, paclitaxel, and bevacizumab, it was hypothesized to improve anti-tumor efficacy by simultaneously inhibiting both DLL4/Notch and VEGF signaling pathways[3][4].